Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine
Weichsel J, Baldauf B, Bonnemeier H, Lau EW, Dittrich S, Cesnjevar R (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 9
Journal Issue: 1
DOI: 10.3390/jcdd9010018
Abstract
Ventricular assist devices (VADs) are used to provide mechanical circulatory support to patients with end-stage heart failure. The driveline connecting the external power source to the pump(s) of the intra-corporal VAD breaches the protective skin barrier and provides a track for microbes to invade the interior of the patient's body. Driveline infection constitutes a major and potentially fatal vulnerability of VAD therapy. Driveline infection cannot traditionally be salvaged and requires the extraction of the entire VAD system. We report here the successful eradication of a VAD driveline infection with a taurolidine-containing antimicrobial solution used for preventing the infection of cardiac implantable electronic devices. If replicated in more cases, the novel treatment concept described here may provide a valuable alternative management strategy of salvage rather than explantation for VAD driveline infection.
Authors with CRIS profile
Sven Dittrich
Professur für Kinderkardiologie
Robert Cesnjevar
Department of Paediatric Cardiac Surgery
Involved external institutions
Germany (DE)
United Kingdom (GB)How to cite
APA:
Weichsel, J., Baldauf, B., Bonnemeier, H., Lau, E.W., Dittrich, S., & Cesnjevar, R. (2022). Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine. Journal of Cardiovascular Development and Disease, 9(1). https://doi.org/10.3390/jcdd9010018
MLA:
Weichsel, Johannes, et al. "Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine." Journal of Cardiovascular Development and Disease 9.1 (2022).
BibTeX: Download